Drug intelligence / Profile preview

vulinacimab

Development stage: Discontinued
Lead developer: Henlius
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Vulinacimab (HLX06) is a fully human monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR-2). By binding to VEGFR-2, it inhibits the VEGF signaling pathway, which plays a critical role in tumor angiogenesis—the formation of new blood vessels that supply nutrients to tumors. Vulinacimab is being developed primarily for the treatment of advanced or metastatic solid tumors and has undergone early-phase clinical trials to assess its safety and efficacy. The drug was originally developed by Henlix Biotech and further developed by Henlius Biopharmaceuticals[1][3][4][7].

Other names: vulinacimabHLX06HLX-06HLX 06

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on vulinacimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vulinacimab.

Explore the full profile